Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Acetazolamide 62.5mg/5ml oral liquid
1106000B0AAAUAU
|
Acetazolamide | Acetazolamide | Eye | No data available |
|
Acetazolamide 65mg/5ml oral suspension
1106000B0AABRBR
|
Acetazolamide | Acetazolamide | Eye | No data available |
|
Acetazolamide 75mg/5ml oral liquid
1106000B0AABIBI
|
Acetazolamide | Acetazolamide | Eye | No data available |
|
Acetest testing tablets
0601060U0BBAAA0
|
Acetest (Reagent) | Urine testing reagents | Endocrine System | No data available |
|
Acetic acid (glacial) 0.94% vaginal gel
0702020B0AAAAAA
|
Acetic acid (Vaginal) | Acetic acid | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Acetic acid (glacial) 5% ear spray
1201010B0AAAGAG
|
Acetic acid (Ear) | Acetic acid | Ear, Nose and Oropharynx | No data available |
|
Acetic acid (glacial) 5% solution
190600000AAAGAG
|
Generic compound preparation BNF 1906000 | Other acid preparations | Other Drugs and Preparations | No data available |
|
Acetic acid 0.5% solution
190600000AAA9A9
|
Generic compound preparation BNF 1906000 | Other acid preparations | Other Drugs and Preparations | No data available |
|
Acetic acid 1% solution
190600000AAA5A5
|
Generic compound preparation BNF 1906000 | Other acid preparations | Other Drugs and Preparations | No data available |
|
Acetic acid 3% solution
190600000AAA2A2
|
Generic compound preparation BNF 1906000 | Other acid preparations | Other Drugs and Preparations | No data available |
|
Acetic acid 33% solution
190600000AABLBL
|
Generic compound preparation BNF 1906000 | Other acid preparations | Other Drugs and Preparations | No data available |
|
Acetohydroxamic acid 250mg capsules
0704030A0AAABAB
|
Acetohydroxamic acid | Acetohydroxamic acid | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Acetyl-L-carnitine 500mg tablets
0206040ALAAABAB
|
Acetyl-l-carnitine | Acetyl-l-carnitine | Cardiovascular System | No data available |
|
Acetyl-NAC 600mg capsules
0307000C0BQACAK
|
Acetyl-NAC | Acetylcysteine | Respiratory System | No data available |
|
Acetylcholine chloride 20mg irrig ampoules
1108020C0AAADAD
|
Acetylcholine chloride (Eye) | Acetylcholine chloride | Eye | No data available |
|
Acetylcholine chloride 20mg irrig vials
1108020C0AAACAC
|
Acetylcholine chloride (Eye) | Acetylcholine chloride | Eye | No data available |
|
Acetylcysteine 0.5% eye drops
1108010C0AAAAAA
|
Acetylcysteine (Eye) | Acetylcysteine | Eye | No data available |
|
Acetylcysteine 100mg granules for oral solution sachets
0307000C0AAALAL
|
Acetylcysteine (Mucolytic) | Acetylcysteine | Respiratory System | No data available |
|
Acetylcysteine 100mg/5ml oral solution
0307000C0AAANAN
|
Acetylcysteine (Mucolytic) | Acetylcysteine | Respiratory System | No data available |
|
Acetylcysteine 20% eye drops
1108010C0AAAGAG
|
Acetylcysteine (Eye) | Acetylcysteine | Eye | No data available |
|
Acetylcysteine 200mg tablets
0307000C0AAAPAP
|
Acetylcysteine (Mucolytic) | Acetylcysteine | Respiratory System | No data available |
|
Acetylcysteine 4% solution
0704040W0AAABAB
|
Acetylcysteine (Bladder) | Acetylcysteine | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Acetylsalicylic acid mixture
0407010B0AAAWAW
|
Aspirin (Analgesic) | Aspirin | Central Nervous System | No data available |
|
Acezide 25mg/50mg tablets
0205051G0BBAAAA
|
Acezide | Co-zidocapt (Hydrochlorothiazide/captopril) | Cardiovascular System | No data available |
|
Achromycin 250mg capsules
0501030V0BBAAAA
|
Achromycin (Systemic) | Tetracycline | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.